Incidence of Cigarette Smoking Relapse Among Individuals Who Switched to e-Cigarettes or Other Tobacco Products.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 10 2021
Historique:
entrez: 19 10 2021
pubmed: 20 10 2021
medline: 12 1 2022
Statut: epublish

Résumé

Although e-cigarettes are not approved as a cessation device, many who smoke believe that e-cigarettes will help them quit cigarette smoking successfully. To assess whether people who recently quit smoking and who had switched to e-cigarettes or another tobacco product were less likely to relapse to cigarette smoking compared with those who remained tobacco free. This cohort study analyzed a nationally representative sample of US households that participated in 4 waves of the Population Assessment of Tobacco and Health Study (conducted 2013 through 2017), combining 2 independent cohorts each with 3 annual surveys. Eligible participants were individuals who smoked at baseline, had recently quit at the first follow-up, and completed the second follow-up survey. Use of e-cigarettes or alternate tobacco products at follow-up 1 after recently quitting smoking. Weighted percentage of participants with over 12 months abstinence by follow-up 2. Of a total of 13 604 participants who smoked cigarettes at baseline, 9.4% (95% CI, 8.7%-10.0%) recently had quit smoking (mean age, 41.9; 95% CI, 39.7-46.6 years; 641 [43.2%] women) Of these, 22.8% (95% CI, 19.7%-26.0%) had switched to e-cigarettes, with 17.6% (95% CI, 14.8%-20.5%) using them daily. A total of 37.1% (95% CI, 33.7%-40.4%) used a noncigarette tobacco product and 62.9% (95% CI, 59.6%-66.3%) were tobacco free. Rates of switching to e-cigarettes were highest for those who were in the top tertile of tobacco dependence (31.3%; 95% CI, 25.0%-37.7%), were non-Hispanic White (26.4%; 95% CI, 22.3%-30.4%), and had higher incomes (annual income ≥$35 000, 27.5%; 95% CI, 22.5%-32.4% vs <$35 000, 19.3%; 95% CI, 16.3%-22.3%). At follow-up 2, unadjusted relapse rates were similar among those who switched to different tobacco products (for any tobacco product: successfully quit, 41.5%; 95% CI, 36.2%-46.9%; relapsed with significant requit, 17.0%; 95% CI, 12.4%-21.6%; currently smoking, 36.2%; 95% CI, 30.9%-41.4%). Controlled for potential confounders, switching to any tobacco product was associated with higher relapse rate than being tobacco free (adjusted risk difference, 8.5%; 95% CI, 0.3%-16.6%). Estimates for those who switched to e-cigarettes, whether daily or not, were not significant. While individuals who switched from cigarettes to e-cigarettes were more likely to relapse, they appeared more likely to requit and be abstinent for 3 months at follow-up 2 (17.0%; 95% CI, 12.4%-21.6% vs 10.4%; 95% CI, 8.0%-12.9%). This large US nationally representative study does not support the hypothesis that switching to e-cigarettes will prevent relapse to cigarette smoking.

Identifiants

pubmed: 34665239
pii: 2785237
doi: 10.1001/jamanetworkopen.2021.28810
pmc: PMC8527352
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2128810

Commentaires et corrections

Type : CommentIn

Références

PLoS One. 2020 Sep 2;15(9):e0237938
pubmed: 32877429
Nicotine Tob Res. 2019 Feb 18;21(3):267
pubmed: 29931122
Prev Chronic Dis. 2017 Apr 13;14:E32
pubmed: 28409740
Am J Public Health. 2021 Feb;111(2):230-246
pubmed: 33351653
JAMA. 2020 Nov 10;324(18):1844-1854
pubmed: 33170240
MMWR Morb Mortal Wkly Rep. 2017 Jan 06;65(52):1457-1464
pubmed: 28056007
Drug Alcohol Depend. 2019 Jun 1;199:10-17
pubmed: 30978519
Nicotine Tob Res. 2019 Feb 18;21(3):278-284
pubmed: 30346585
N Engl J Med. 2019 Feb 14;380(7):629-637
pubmed: 30699054
Int J Environ Res Public Health. 2019 Dec 11;16(24):
pubmed: 31835841
JAMA Netw Open. 2020 Jun 1;3(6):e204813
pubmed: 32501492
Drug Alcohol Depend. 2021 Jul 1;224:108724
pubmed: 33940324
Am J Epidemiol. 2020 Dec 1;189(12):1529-1537
pubmed: 32715314
Drug Alcohol Depend. 2020 Sep 1;214:108134
pubmed: 32629146
Am J Epidemiol. 2018 Nov 1;187(11):2397-2404
pubmed: 29955810
Tob Control. 2007 Apr;16(2):85-90
pubmed: 17400944
J Natl Cancer Inst. 1997 Apr 16;89(8):572-6
pubmed: 9106646
Cochrane Database Syst Rev. 2019 Oct 28;2019(10):
pubmed: 31684681
Environ Int. 2019 Feb;123:201-208
pubmed: 30530162
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901

Auteurs

John P Pierce (JP)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.
Moores Cancer Center, University of California, San Diego, La Jolla.

Ruifeng Chen (R)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.

Sheila Kealey (S)

Moores Cancer Center, University of California, San Diego, La Jolla.

Eric C Leas (EC)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.
Moores Cancer Center, University of California, San Diego, La Jolla.

Martha M White (MM)

Moores Cancer Center, University of California, San Diego, La Jolla.

Matthew D Stone (MD)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.

Sara B McMenamin (SB)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.

Dennis R Trinidad (DR)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.
Moores Cancer Center, University of California, San Diego, La Jolla.

David R Strong (DR)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.
Moores Cancer Center, University of California, San Diego, La Jolla.

Tarik Benmarhnia (T)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.
Moores Cancer Center, University of California, San Diego, La Jolla.
Scripps Institution of Oceanography, University of California, San Diego, La Jolla.

Karen Messer (K)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla.
Moores Cancer Center, University of California, San Diego, La Jolla.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH